Sorry, no content matched your criteria.
Featured Story
Score an Extra 655% with EKSO - Make Your Move Now
We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year.
And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share.
We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year.
And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share.